Inflexion’s Rosemont Pharmaceuticals agrees deal for Aytu BioPharma at 41.1 percent premium

Aytu is a US specialty pharmaceutical company focused on central nervous system diseases, with an ADHD portfolio and a depression treatment.

18 minutes ago•2 mins read
LinkedInXEmail
LinkedInXEmail